Prostate Cancer Spread may be Delayed With Apalutamide

Apalutamide - drug under development for prostate cancer yields promising result The progress of prostate cancer may be slowed down by treatment with the drug apalutamide. Research at the Massachusetts General Hospital finds that treatment with the investigational androgen receptor inhibitor - apalutamide, significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.